Price
907.1
-1.06%52W Range
Market Cap
₹68,482.25 Cr
Traded: ₹73.82 Cr (0.11%) 0.0x
Free Float: ₹5,122.47 Cr (1.44% of FF traded)
Volume · 60D trend
8.13 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +8.0% | +18.0% | +13.0% | -- | +17.0% | Stable |
| Profit | +60.0% | +64.0% | +27.0% | -- | +26.0% | Decelerating |
| Return | +20.0% | +33.0% | +51.0% | +27.0% | -- | Stable |
| ROE | +5.0% | +9.0% | +10.0% | -- | -- | Accelerating |
Quarterly Results
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,545 | 2,365 | 2,265 | 2,331 | 2,167 | 2,007 | 1,928 | 1,988 | 1,859 | 1,786 | 1,680 | 1,770 | 1,657 | 1,643 | 1,560 | 1,607 |
| Expenses | 2,008 | 1,832 | 1,759 | 1,775 | 1,676 | 1,572 | 1,553 | 1,554 | 1,516 | 1,405 | 1,396 | 1,440 | 1,386 | 1,372 | 1,283 | 1,304 |
| Operating Profit | 537 | 532 | 506 | 556 | 491 | 435 | 375 | 435 | 343 | 381 | 284 | 330 | 272 | 271 | 276 | 303 |
| OPM % | 21.0% | 23.0% | 22.0% | 24.0% | 23.0% | 22.0% | 19.0% | 22.0% | 18.0% | 21.0% | 17.0% | 19.0% | 16.0% | 16.0% | 18.0% | 19.0% |
| Other Income | 28 | -2 | -34 | 50 | 31 | -29 | 47 | -42 | 14 | 17 | 19 | 18 | 10 | 26 | 26 | 75 |
| Interest | 80 | 84 | 86 | 75 | 70 | 68 | 45 | 36 | 35 | 35 | 33 | 32 | 31 | 32 | 33 | 33 |
| Depreciation | 122 | 122 | 120 | 106 | 101 | 102 | 97 | 95 | 91 | 92 | 87 | 84 | 79 | 82 | 83 | 77 |
| Profit Before Tax | 363 | 324 | 266 | 425 | 351 | 237 | 279 | 261 | 230 | 271 | 183 | 233 | 171 | 183 | 186 | 268 |
| Tax % | 25.0% | 16.0% | 26.0% | 23.0% | 24.0% | 21.0% | 9.0% | 26.0% | 24.0% | 25.0% | 27.0% | 21.0% | 27.0% | 25.0% | 24.0% | 19.0% |
| Net Profit | 273 | 271 | 197 | 329 | 267 | 188 | 254 | 193 | 174 | 203 | 134 | 184 | 124 | 138 | 142 | 218 |
| Exceptional Items | -- | -12 | -46 | 24 | 13 | -54 | 24 | -60 | 0 | 3 | 8 | 4 | 1 | 11 | 11 | 52 |
| EPS (Rs) | 3.5 | 3.5 | 2.6 | 4.3 | 3.5 | 2.4 | 3.3 | 2.3 | 2.2 | 2.4 | 1.8 | 2.3 | 1.5 | 1.8 | 1.7 | 2.7 |
| Sales Growth (YoY) | -- | 17.8% | 17.5% | 17.3% | 16.6% | 12.4% | 14.8% | 12.3% | 12.2% | 8.7% | 7.7% | 10.1% | 11.4% | 19.2% | -- | -- |
| Sales Growth (QoQ) | -- | 4.4% | -2.8% | 7.6% | 8.0% | 4.1% | -3.0% | 6.9% | 4.1% | 6.3% | -5.1% | 6.8% | 0.8% | 5.3% | -2.9% | -- |
| OP Growth (YoY) | 9.4% | 22.3% | 34.9% | 27.8% | 43.1% | 14.2% | 32.0% | 31.8% | 26.1% | 40.6% | 2.9% | 8.9% | -- | -- | -- | -- |
| OP Growth (QoQ) | 0.9% | 5.1% | -9.0% | 13.2% | 12.9% | 16.0% | -13.8% | 26.8% | -10.0% | 34.2% | -13.9% | 21.3% | 0.4% | -1.8% | -8.9% | -- |
| Profit Growth (YoY) | -- | 22.0% | 0.0% | 40.0% | 51.0% | 28.0% | 76.0% | 27.0% | 50.0% | 41.0% | 6.0% | 4.0% | -9.0% | 84.0% | 9.0% | 55.0% |
| EPS Growth (YoY) | -- | 44.3% | -21.6% | 82.0% | 56.8% | 3.0% | 84.3% | 1.7% | 48.6% | 34.7% | 3.5% | -15.1% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 37.0% | -39.7% | 23.5% | 41.4% | -25.6% | 40.2% | 6.4% | -7.2% | 33.1% | -22.6% | 55.4% | -15.9% | 2.3% | -36.5% | -- |
| OP Margin | -- | 22.5% | 22.3% | 23.9% | 22.7% | 21.7% | 19.4% | 21.9% | 18.4% | 21.3% | 16.9% | 18.6% | 16.4% | 16.5% | 17.7% | 18.9% |
| Net Margin | -- | 11.5% | 8.7% | 14.1% | 12.3% | 9.4% | 13.2% | 9.7% | 9.4% | 11.4% | 8.0% | 10.4% | 7.5% | 8.4% | 9.1% | 13.6% |
| Material Cost % | -- | 21.9% | 22.8% | 23.1% | 23.7% | 23.1% | 23.5% | 23.2% | 24.4% | 23.2% | 23.4% | 23.3% | 24.0% | 23.3% | 23.0% | 22.7% |
| Employee Cost % | -- | 14.4% | 14.5% | 13.6% | 14.4% | 14.3% | 15.3% | 14.6% | 15.9% | 15.2% | 16.8% | 15.9% | 17.2% | 15.9% | 16.8% | 16.7% |
| P/S | 7.20 | 7.61 | 8.34 | 8.44 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 65.35 | 66.67 | 76.15 | 70.19 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 6.92 | 7.02 | 7.76 | 7.55 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Relevant disclosure attached
Relevant disclosure attached
The relevant disclosure is attached.
Proceeding of 30th Annual General Meeting
Relevant disclosure is attached
Relevant disclosure is attached
The Relevant disclosure is attached
Appointment of Tax Auditor
The relevant disclosure is attached.
The relevant disclosure is attached.
The relevant disclosure is attached
Relevant disclosure is attached.
The relevant disclosure is attached.
Company has fixed the closure of Register of Menbers
Company has fix the Record date for payment of Dividend
Letters sent to the shareholders containing the weblink to access the Annual Report FY 2025-2026
Bussiness Resposibilty and Sustainability report for FY 2025-2026
Annual Report for FY 2025-2026
Notice of Annual General Meeting
Copy of Newspaper publication.
The relevant dislosure is attached.
Relevant disclosure is attached.
Fortis Healthcare Limited has informed the Exchange regarding Outcome of Board Meeting held on July 08, 2026 regarding re-appointment of Dr. Ashutosh Raghuvanshi as Managing Director (designated ....
Relevant Disclosure is attached.
The relevant disclosure is attached.
The relevant disclosure is attached.
The Intimation is regarding an update on the Income Tax Order received by Fortis Hospitals Limited (Wholly Owned Subsidiary of the Company)
Annual Secretarial Compliance Report for the Financial Year ended March 31, 2026
Relevant disclosure attached
Relevant disclosure attached
Relevant disclosure attached
Relevant disclosures attached
Relevant disclosures attached
Relevant disclosures attached
Appointment of Cost Auditor
Relevant Disclosure attached
Relevant disclosures attached
investor presentation
Approval of Financial results for the Quarter and Year Ended March 31, 2026 and Recommendation of Final Dividend for the Year Ended March 31, 2026.
Financial results for the Quarter and Year ended March 31, 2026
the relevant disclosures are attached.
Fortis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2026 ,inter alia, to consider and approve the Audited Financial Results ....
The relevant disclosure is attached.
Relevant disclosure is attached
The relevant disclosure is attached
The relevant disclosure is attached.
Please Find the relevent disclosure attached
The relevant disclosure is attached.
The relevant disclosure is attached.
This intimation is regarding an update on the Income Tax Order received by Fortis Hospitals Limited (Wholly Owned Subsidiary of the Company).
Annual Reports
14Credit Ratings
6Concalls
40Feb 2026
28 Feb 2026Jan 2026
31 Jan 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024May 2024
31 May 2024May 2024
31 May 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023Aug 2023
31 Aug 2023May 2023
31 May 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022May 2022
31 May 2022May 2022
31 May 2022Aug 2021
31 Aug 2021May 2021
31 May 2021Jun 2020
30 Jun 2020Feb 2020
29 Feb 2020Jun 2019
30 Jun 2019Feb 2019
28 Feb 2019Jul 2018
31 Jul 2018Jun 2018
30 Jun 2018Mar 2018
31 Mar 2018Aug 2017
31 Aug 2017May 2017
31 May 2017Feb 2017
28 Feb 2017Aug 2016
31 Aug 2016May 2016
31 May 2016Feb 2016
29 Feb 2016Held by ETFs
45 ETFs hold fortis · sorted by weight
Held by Mutual Funds
171 schemes hold fortis · sorted by weight